What is your approach to the use of denosumab in patients with metastatic breast cancer with bony involvement?

I do not extrapolate the results of OPTIMIZE-2 and CALGB 70604 to denosumab. It is a different drug and until appropriate studies are performed, there is no reason to change its dose or schedule.